Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø

XClose

Early Phase Cancer Trials Programme at Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø and Ïã¸ÛÁùºÏ²ÊÖÐÌØÍøH

Home
Menu

Brain Trials

A LIST OF OUR EARLY PHASE brain cancerÌýTRIALS WHICH ARE OPEN TO RECRUITMENT AT UNIVERSITY COLLEGE LONDON HOSPITALs

To find more information on Ïã¸ÛÁùºÏ²ÊÖÐÌØÍøH Early Phase Cancer Clinical Trials, including eligibility criteria, click theÌýhyperlinkedÌýLocal Project Reference (LRP)ÌýID, which will take you to the Ïã¸ÛÁùºÏ²ÊÖÐÌØÍøH Find a Study database.

Ìý

CITADEL-123

A Phase I clinical trial to assess the activity of I-123 Poly Adenosine Diphosphate Ribose Polymerase I inhibitor (123I-ATT001) directly administered in subjects with relapsed glioblastoma

Local Project Reference:
Principal Investigator:Dr Paul Mulholland
Drug Class/ Treatment:

123I-ATT001Ìý(I-123 Poly Adenosine Diphosphate Ribose Polymerase I inhibitor)

Intracavitary instillation

Patient Population:Relapsed Glioblastoma
Trial Hosted By - Ïã¸ÛÁùºÏ²ÊÖÐÌØÍøH Clinical Research Facility (CRF)

Ìý

LOXO-RET-18036

A Phase 1/2 Study of the Oral RET Inhibitor LOXO-292 in Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System TumoursÌý

Local Project Reference:
Principal Investigator

Dr Sara Stoneham

Drug Class/ Treatment:

Selpercatinib (LOXO-292)Ìý(RET Inhibitor)

Patient Population:

Paediatric patients ≥ 6 months of age and ≤ 21 years of age at Cycle 1 Day 1 (C1D1)

  • RET fusion-positive solid tumor with measurable disease
  • RET-mutant MTC with measurable disease
  • RET fusion-positive primary CNS tumor with measurable disease.

Trial Hosted By - Ïã¸ÛÁùºÏ²ÊÖÐÌØÍøH Cancer Clinical Trials Unit (CCTU)

Ìý